Understanding Your Breast Cancer: IHC ER-PR Hormone Receptor Testing
When you’re facing a breast cancer diagnosis, the uncertainty can feel overwhelming. We understand that every piece of information matters in your treatment journey. The IHC ER-PR test provides crucial insights into whether your cancer responds to hormone therapy – information that could significantly impact your treatment success and quality of life.
What Does the IHC ER-PR Test Detect?
This specialised test examines your breast tissue for estrogen and progesterone receptors – proteins that determine if your cancer cells are “fueled” by hormones. When these receptors are present (ER-positive or PR-positive), it means hormone-blocking treatments can be highly effective. Understanding this biological characteristic of your cancer helps your oncologist create the most targeted, effective treatment plan specifically for you.
Who Should Consider This Test?
This test is essential for anyone with a new breast cancer diagnosis. It’s particularly crucial if you’re experiencing:
- Recent breast cancer diagnosis requiring treatment planning
- Need for personalised hormone therapy decisions
- Planning for targeted cancer treatment strategies
- Requirement for comprehensive cancer profiling
Early testing provides the foundation for the most effective treatment approach, giving you the best possible outcomes.
Why This Test Matters for Your Health Journey
Knowing your hormone receptor status transforms uncertainty into actionable information. This knowledge helps:
- Guide Treatment Decisions: Determine if hormone therapy will be effective for your specific cancer type
- Personalise Your Care: Create a treatment plan tailored to your cancer’s biological characteristics
- Improve Outcomes: Target the right treatments from the start for better results
- Reduce Side Effects: Avoid unnecessary treatments that won’t work for your cancer type
- Provide Peace of Mind: Make informed decisions with confidence about your treatment path
Understanding Your Results – Clear Guidance for Your Journey
We know waiting for results can be anxiety-provoking. Our comprehensive report clearly explains whether your cancer is:
- ER-Positive/PR-Positive: Your cancer responds to hormone therapy – opening effective treatment options
- ER-Negative/PR-Negative: Your cancer doesn’t use hormones to grow – guiding alternative treatment approaches
Your results come with clear explanations and are designed to be easily understood when discussing with your oncologist. We’re here to support you through every step of this process.
Transparent Pricing – Value That Makes Sense
| Test Description | Regular Price | Special Price |
|---|---|---|
| IHC ER-PR Hormone Receptor Test | ZAR 1,350 |
Turnaround Time: 3 working days
Sample Required: Tissue in 10% Neutral Buffered Formalin OR Paraffin Block
This investment in precise diagnosis can save thousands in ineffective treatments and provide priceless peace of mind.
Why Trust Oracle Genomics?
We understand that accuracy matters when it comes to cancer diagnosis. Our commitment to you includes:
- Nationwide Coverage: Accessible testing across South Africa including Johannesburg, Cape Town, Durban, and Pretoria
- Medical Expertise: Specialised oncology testing with proven accuracy
- Quick Turnaround: Results within 3 working days to reduce your waiting anxiety
- Patient-Centred Care: We treat every sample with the understanding that it represents someone’s health journey
- Quality Assurance: Rigorous quality controls ensuring reliable results you can trust
Take Control of Your Treatment Journey Today
Don’t let uncertainty dictate your cancer treatment. With accurate hormone receptor testing, you can move forward with confidence in your treatment plan. Our team is ready to support you through this critical step in your healthcare journey.
Note: This test requires a doctor’s prescription for most cases. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Ready to get the answers you need? Book your IHC ER-PR test today and take the first step toward targeted, effective cancer treatment.
